Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition

Carcinogenesis

Volumn 36, Issue 4, 2014, Pages 459-468

  Liu, Hong ^a,c   Ren, Guoping ^a   Wang, Tingyang ^a   Chen, Yuexia ^a   Gong, Chaoju ^a   Bai, Yanfeng ^a   Wang, Bo ^a   Qi, Hongyan ^a   Shen, Jing ^a   Zhu, Lijun ^a   Qian, Cheng ^b   Lai, Maode ^a   Shao, Jimin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Jinhua People's Hospital Jinhua Polytechnic College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; PROTEIN ZO1; STAT3 PROTEIN; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; DNA BINDING PROTEIN; IL6 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN C FOS; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HT 29 CELL LINE; LIVER TUMOR; METABOLISM; SECONDARY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HT29 CELLS; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; LYMPHATIC METASTASIS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-FOS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84927628854     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv017     Document Type: Article

References (50)

1. Center, M.M. et al. (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol. Biomarkers Prev., 18, 1688-1694.
2. Andre, N. et al. (2005) Chemoradiotherapy for colorectal cancer. Gut, 54, 1194-1202.
3. Ullman, T.A. et al. (2011) Intestinal inflammation and cancer. Gastroenterology, 140, 1807-1816.
4. Grivennikov, S. et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-113.
5. Bollrath, J. et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
6. Rokavec, M. et al. (2014) IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest., 124, 1853-1867.
7. Ataie-Kachoie, P. et al. (2013) Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev., 24, 163-173.
8. Komoda, H. et al. (1998) Interleukin-6 levels in colorectal cancer tissues. World J. Surg., 22, 895-898.
9. Knüpfer, H. et al. (2010) Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int. J. Colorectal Dis., 25, 135-140.
10. Young, M.R. et al. (2006) Fra-1 a target for cancer prevention or intervention. Gene, 379, 1-11.
11. Kustikova, O. et al. (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol. Cell. Biol., 18, 7095-7105.
12. Lombaerts, M. et al. (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer, 94, 661-671.
13. Tam, W.L. et al. (2013) Protein kinase C a is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell, 24, 347-364.
14. Caramel, J. et al. (2013) A switch in the expression of embryonic EMTinducers drives the development of malignant melanoma. Cancer Cell, 24, 466-480.
15. Diesch, J. et al. (2014) Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One, 9, e88950.
16. Yuan, Z.L. et al. (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science, 307, 269-273.
17. Al Zaid Siddiquee, K. et al. (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 18, 254-267.
18. Brabletz, T. et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U. S. A., 98, 10356-10361.
19. Yang, J. et al. (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell, 14, 818-829.
20. Bates, R.C. et al. (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol. Ther., 4, 365-370.
21. Yang, Y. et al. (2006) Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res., 66, 8617-8624.
22. Lo, H.W. et al. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res., 67, 9066-9076.
23. Guo, L. et al. (2013) Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene, 32, 5272-5282.
24. Singh, B.N. et al. (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther., 10, 935-954.
25. Qi, H. et al. (2012) Interferon regulatory factor 1 transactivates expression of human DNA polymerase η in response to carcinogen N-methyl-N'-nitro-N-nitrosoguanidine. J. Biol. Chem., 287, 12622-12633.
26. Sun, Y. et al. (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol., 182, 5899-5903.
27. Kundumani-Sridharan, V. et al. (2012) Novel interactions between NFATc1 (nuclear factor of activated T cells c1) and STAT-3 (signal transducer and activator of transcription-3) mediate G protein-coupled receptor agonist, thrombin-induced biphasic expression of cyclin D1, with first phase influencing cell migration and second phase directing cell proliferation. J. Biol. Chem., 287, 22463-22482.
28. Lee, H. et al. (2012) Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U. S. A., 109, 7765-7769.
29. Li, J. et al. (2013) STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer. Oncol. Rep., 30, 165-170.
30. Lee, J.L. et al. (2009) Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J. Cell Biol., 185, 949-957.
31. Su, Y.J. et al. (2011) Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J., 30, 3186-3199.
32. Ohbayashi, N. et al. (2007) LIF-and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol. Pharm. Bull., 30, 1860-1864.
33. Nie, Y. et al. (2009) STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol., 11, 492-500.
34. Icardi, L. et al. (2012) The HAT/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev., 23, 283-291.
35. Yue, P. et al. (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs, 18, 45-56.
36. Andreolas, C. et al. (2008) Fra-1 regulates vimentin during Ha-RASinduced epithelial-mesenchymal transition in human colon carcinoma cells. Int. J. Cancer, 122, 1745-1756.
37. Stinson, S. et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal, 4, ra41.
38. Sullivan, N.J. et al. (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene, 28, 2940-2947.
39. Peinado, H. et al. (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415-428.
40. Huang, C. et al. (2011) The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma, 58, 396-405.
41. Maschler, S. et al. (2010) Annexin A1 attenuates EMT and metastatic potential in breast cancer. EMBO Mol. Med., 2, 401-414.
42. Dauer, D.J. et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene, 24, 3397-3408.
43. Rojas, A. et al. (2011) IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 30, 2345-2355.
44. Adiseshaiah, P. et al. (2005) Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements. Oncogene, 24, 4193-4205.
45. Yang, S. et al. (2013) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene, 32, 4294-4303.
46. Belguise, K. et al. (2012) The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene, 31, 4889-4897.
47. Fleischmann, A. et al. (2000) Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev., 14, 2695-2700.
48. Bakiri, L. et al. (2007) Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bone, 40, 867-875.
49. Singh, A. et al. (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29, 4741-4751.
50. Rhim, A.D. et al. (2012) EMT and dissemination precede pancreatic tumor formation. Cell, 148, 349-361.